These studies provide evidence of the requirement of STAT3 signaling in immune evasion mechanisms in a range of cell types within the tumor microenvironment; however, to date there is little known of the exact mechanism underpinning STAT3-dependent antitumor immunity in metastatic breast cancer, and thus, this merits further interrogation to determine its potential in enhancing cancer immunotherapies. The gene discussed is STAT3; the disease is neoplasm.